How to treat hypertension in blacks: Review of the evidence

Acta Clinica Belgica

Volumn 64, Issue 6, 2009, Pages 466-476

  Kola, L D ^a,b   Sumaili, E K ^b   Krzesinski, Jean Marie ^b  

^a Centre Hospitalier Du Bois de L'Abbaye   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

African Americans; Antihypertensive treatment; Arterial hypertension; Hypertensive blacks; Hypertensive complications; Sub Saharan Africans

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; RENIN; THIAZIDE DIURETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GENETIC DIFFERENCE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NEGRO; ONSET AGE; PLASMA RENIN ACTIVITY; POTASSIUM INTAKE; PROGNOSIS; RACE DIFFERENCE; SALT INTAKE; SOCIOECONOMICS;

EID: 75149158091     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2009.082     Document Type: Article

References (90)

1. Hypertension Detection and Follow-up Program Cooperative Group: Race, education, and prevalence of hypertension. Am J Epidemiol 1977; 106: 351-361.
2. Toto RD, Hypertensive nephrosclerosis in African Americans. Kidney Int 2003; 64: 2331-2341.
3. Cooper RS, Kaufman JS. Race and hypertension. Hypertension 1998; 32: 813-816.
4. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 1997; 277: 1293-1298.
5. Deedat Yk. Recommendations for hypertension in sub-Saharan Africa. Cardiovasc J S Afr 2004; 15: 157-158.
6. Silwa K, Wilkinson D, Hansen C, et al. Spectrum of Heart Disease and Risk Factors in a Black Urban Population in South Africa (The Heart of Soweto Study): A Cohort Study. Lancet 2008; 371: 915-922.
7. White HD, Dalby AJ. Heart disease in Soweto: facing a triple threat. Lancet 2008; 371: 876-877.
8. Vorster HH. The emergence of cardiovascular disease during urbanisation of Africans. Public Health Nutr 2002; 5: 239-243.
9. Addo J, Smeeth L, Leon DA. Hypertension in Sub-Saharan Africa. A Systematic Review. Hypertension 2007; 50: 1012-1018.
10. Brown NJ. Hypertension and ethnic group. BMJ 2006; 332: 833-836.
11. Douglas JG, Wright JT Jr Blacks and Hypertension. Kalamazoo, Upjohn Company, 1992.
12. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27 (part 2): 481-490.
13. Luft FC, Miller JZ, Grim CE, et al. Salt sensitivity and resistance of blood pressure: Age and race as factors in physiological responses. Hypertension 1991; 17: 1102-1108.
14. Harshfield GA, Alpert BS, Pullam DA, et al. Sodium excretion and racial differences in ambulatory blood pressure patterns. Hypertension 1991; 18: 813-818.
15. Luft FC, Grim CE, Higgins JT, Weinberger MH . Differences in response to sodium administration in normotensive white and black subjects. J Lab Clin Med 1977; 90: 555-562.
16. Aviv A, Hollenberg NK, Weder AB. Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African- Americans. Kidney Int 2004; 65: 361-368.
17. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: Racial differences. J Hypertens 1997; 15: 545-550.
18. Juan Oliver. Vasopressin regulates the renin-angiotensin-aldosterone system Am J Physiol Renal Physiol 2008; 295: F100-F107.
19. Jeck N, Waldegger S, Lampert A. et al. Activating Mutation of the Renal Epithelial Chloride Channel CIC-Kb Predisposing to Hypertension. Hypertension 2004; 43: 1175-1181.
20. Falkner B. Differences in blacks and whites with essential hypertension: biochemistry and endocrine: state of the art lecture. Hypertension 1990; 15: 681-686.
21. Luft FC, Grim CE, Fineberg N, Weinberger MC. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation 1979; 59: 643-650.
22. Freis ED, Materson BJ, Flamenbaum W. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med 1983; 74: 1029-1041.
23. Fray JCS: (pro) Renin processing and secretion in black essential hypertension and other low-renin syndromes. In Fray JCS, Douglas JG (eds): Pathophysiology of Hypertension in Blacks. Oxford University Press for the American Physiological Society, 1993, pp 214-238.
24. Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA 1979; 241: 151-156.
25. Pratt JH, Jones JJ, Miller JZ Wagner MA, Fineberg NS. Racial differences in aldosterone excretion and plasma aldosterone concentrations in children. N Engl J Med 1989; 321: 1152-1157.
26. Fisher ND, Gleason RE, Moore JT, Williams GH, Hollenberg NK. Regulations of aldosterone secretion in hypertensive blacks. Hypertension 1994; 23: 179-184.
27. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 1981; 291: 329-331.
28. Li S, McAlpine DD, Liu J, Collins AJ. Differences between blacks and whites in the incidence of end-stage renal disease and associated risk factors. Adv Ren Replace There 2004; 11: 5-13.
29. Appel LJ, Wright JT Jr, Greene T, et al. Long- term Effects of Renin-Angiotensin System-Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. Arch Intern Med 2008; 168: 832-839.
30. Parmer RJ, Stone RA, Cervenka JH. Renal hemodynamics in essential hypertensions. Racial differences in response to changes in dietary sodium. Hypertension 1994; 24: 752-757.
31. Klag MJ, Whelton PK, Coresh J, Grim CE, et al. The association of skin colour with blood pressure in US blacks with low socio-economic status. JAMA 1991; 265: 599-602.
32. Sorel JE, Ragland DR, Seyme SL, et al. Educational status and blood pressure. The Second National Health and Nutrition Examination Survey, 1976-1980, and The Hispanic Health and Nutrition Examination Survey, 1982-1984. Am J Epidemiol 1992; 175: 1339-1348.
33. Starfield B, Powe NR, Weiner JR, et al. Costs vs quality in different types of primary care settings. JAMA 1994; 272: 1903-1908.
34. Cooper R, Rotimi C, Ataman S et al. Hypertension prevalence in seven populations of African origin. Am J Public Health 1997; 87: 160-184.
35. Chiang BN, Perlman LV, Epstein FH. Overweight and hypertension: a review. Circulation 1969; 39: 403-421.
36. Hypertension Detection and Follow-up Program Cooperative Group: Five year findings of the hypertension detection and follow-up program. II. Mortality by race, sex and age. JAMA 1979; 242: 2572-2577.
37. Hebert LA, Agarwal G, Ladson-Wofford SE, et al. Nocturnal blood pressure in treated hypertensive African-Americans compared to treated hypertensive European Americans. J Am Soc Nephrol 1996; 7: 2130-2134.
38. Curry CL Coronary artery disease in African-Americans. Circu lation 1991; 83: 1474-1475.
39. Taylor JO, Borhani NO, Entwisle G, Farber N, Hawkins CM. (Hypertension detection and follow-up program). Summary of the baseline characteristics of the hypertensive participants. Hy pertension 1983; 5 (Suppl IV): IV44-IV50.
40. Akinboboye O, Idris O, Akinkugbe O. Trends in coronary artery disease and associated risk factors in sub-Saharan Africans. J Hum Hypertens 2003; 17: 381-387.
41. Steyn K, Sliwa K, Hawken S, et al. Risk factors associated with myocardial infarction in Africa: the Interheart Africa Study. Cir culation 2005; 112: 3554-3561.
42. Rosamond W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics-2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
43. Caplan LR. Strokes in African-Americans. Circulation 1991; 83: 1469-1471.
44. Connor MD, Thorogood M, Casserly B, et al. Prevalence of stroke survivors in rural South Africa: results from the Southern Africa Stroke Prevention Initiative (SASPI) Agincourt field site. Stroke 2004; 35: 627-632.
45. Cruickshank JK, Mbanya JC, Wilks R et al. Hypertension in four African-origin populations: current 'rule of halves', quality of blood pressure control and attributable risk of cardiovascular disease. J Hypertens 2001;19: 41-46.
46. Okosun I, Cooper RS, Muna W. Epidemiology of stroke in African populations outside of the United States. In: Gillum R, Gorelide P, Cooper E, eds. Stroke in Blacks. Basel: Karger; 1999: 70-82.
47. Opie LH, Seedat YK. Hypertension in Sub-Saharan African Populations. Circulation 2005; 112: 3562-3568.
48. Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med 1992; 326: 733-736.
49. Klatsky AL, Armstrong MA, Friedman GD. Racial differences in cerebrovascular disease hospitalizations. Stroke 1991; 22: 299-304.
50. Powers DR, Wallin JD. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med 1998; 158: 753-800.
51. Norris KC, Hornhill-Joynes M, Robinson C, et al. Cocaine use, hypertension, and end-stage renal disease. Am J Kidney Dis 2001; 38: 523-528.
52. Anderson S, Brenner BM. The critical role of nephron mass and of intraglomerular pressure for initiation and progression of experimental hypertensive-renal disorders (chapter 73), in Hypertension: Pathophysiology, diagnosis & Management, edited by Laragh JH, Brenner BM, New-York, 1990: 1163-1178.
53. Li S, Chen SC, Shlipak M, et al. and Kidney Early Evaluation Program Investigators Chronic Disease Research Group. Low birth weight is associated with chronic kidney disease only in men. Kidney Int 2008; 73(5): 637-642.
54. Krzesinski J-M, Cohen E.P. Hypertension and the Kidney. Acta Clinica Belgica 2007; 62(1),5-14.
55. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47: 296-308.
56. Lemogoum D, Seedat YK, Mabadeje AF, et al. International Forum for Hypertension Control and Prevention in Africa. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2003;21: 1993-2000.
57. Kokkinos PF, Narayan P, Colleran JA, et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med 1995; 333: 1462-1467.
58. Swift PA, Markandu ND, Sagnella GA, et al. Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trials. Hypertension 2005; 46: 308-312.
59. Seedat JK, Varying responses to hypotensive agents in different racial groups: black versus white differences. J Hypertens 1989; 7: 515-518.
60. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
61. Materson BJ, Reda DJ, Cushman WC, et al. For the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents, (correction: N Engl J Med 1994; 330: 1689). N Engl J Med 1993; 328: 914-921.
62. The ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
63. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-2015.
64. Wright JT Jr, Dunn JK, Cutler JA et al. For the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and non black patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293: 1595-1608.
65. Pratt JH, Ambrosius WT, Agarwal R, Eckert GJ, Newman S. Racial difference in the activity of the amiloride-sensitive epithelial sodium channel. Hypertension 2002; 40: 903-908.
66. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46: 481-487.
67. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol 2003; 41: 1148-1155.
68. Sareli P, Radevski IV, Valtchanova ZP, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med 2001; 161: 965-971.
69. Saunders E, Weir MR, Kong BW et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-1713.
70. Dallas HW, Reed JW, Flack JM, Yunis C, Preisser J and the ISHIB Investigators Group. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. Arch Intern Med 1998; 158: 2029-2034.
71. Weir MR, Ferdinand KC, Flack JM, et al. For the ADVANCE Investigators. A non inferiority comparison of valsartan/hydrochlorothiazide combinations versus amlodipine in black hypertensives. Hypertension 2005; 46: 508-513.
72. Maciejewski S, Mohiuddin SM, Packard KA, et al. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring. Pharmacotherapy 2006 ; 26: 889-895.
73. Wright JT Jr, Dunn JK, Cutler JA, et al. For the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine and lisinopril. JAMA 2005, 293: 1595-1507.
74. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60(1): 8-13.
75. Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 1996; 60(5): 582-588.
76. Middlemost SJ , Tager RT, David JD, Sareli P. Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. Am J Cardiol 1994; 73: 1092-1097.
77. Weir MR, Gray JM, Paster R, Saunders E. For the Trandolapril Multicenter Study Group. Differing mechanisms of action of angiotensin- converting enzyme inhibition in black and white hypertensive patients. Hypertension 1995; 26: 124-130.
78. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for initial treatment of hypertension:I. Results of short-term titration with emphasis on racial differences in response. JAMA 1982; 248: 1996-2003.
79. Bosman AR, Goldberg B, et al. South African multicenter study of metoprolol and propranolol in essential hypertension. S Afr Med 1977; 51: 57-61.
80. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol 1983; 52: 1230-1237.
81. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African-American patients. J Clin Hypertens 2007; 9: 866-875.
82. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high risk and low-risk patients after myocardial Infarction. N Engl J Med 1998; 339: 489-497.
83. Dargie HJ. Effect of Carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-1390.
84. Agodoa LY, Appel L, Bakris GL, et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis : a randomized controlled trial. JAMA 2001; 285: 2719-2728.
85. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African-Americans: consensus statement of the Hypertension in African-Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163: 525-541.
86. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/ DOQI Clinical Practice Guidelines on Hypertension and antihypertensive agents in chronic Kidney disease. Am J Kidney Dis 2004; 43 (5) (suppl1): S1-S29.
87. European Society for Hypertension-European Society of Cardiology Guidelines Committee. 2007 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.
88. Veterans Administration Cooperative Study Group on Antihypertensive. Agents.Racial differences in response to low-dose Captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982; 14 (suppl 2): 97S-101S.
89. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch In tern Med 1997; 157: 2413-2466.
90. Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J. Hypertens 1999; 17: 151-183.